Alfredo Addeo, Head of the Oncology Department at University Hospitals of Geneva, shared a post on X about a recent article by Roni Levina et al, adding:
“The rise of subcutaneous immunotherapy isn’t just about convenience, it’s about patents, pricing strategies, and delayed biosimilars.
Can healthcare systems afford years of high prices when IV biosimilars could generate huge savings?
Brilliant and provocative viewpoint.”
Title: Subcutaneous immunotherapy—a wolf in sheep’s clothing?
Authors: Roni Levina, Amol Akhade, Manju Sengar, Daniel A Goldstein
Read the Full Article on The Lancet Oncology
More posts featuring Subcutaneous Immunotherapy.